The Endpoints Slack interview: How Beam CEO John Evans thinks about the science and business of genetic editing
05 Feb 2024
Even with last year’s landmark approvals for genetic medicines in sickle cell disease, John Evans is convinced his startup can push the field further.
Beam Therapeutics started 2024 by announcing it had dosed the first sickle cell patient with its base-editing program, expecting initial human results in the second half of 2024. Endpoints News invited Evans, a former Agios Pharmaceuticals executive who has run Beam since 2017, to our secret Slack channel to talk about Beam’s sickle cell plans amid increasing competition, as well as how CRISPR could evolve over the next two decades.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.